Zoetis Inc. (ZTS)
NYSE • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Zoetis Inc. keeps $25 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 11
in 81 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Zoetis beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported November 5, 2026, with adjusted EPS of $1.75 topping the $1.51 estimate (+15.9%) as revenue of $2.391 billion topped the $2.304 billion consensus (+3.8%) even as sales slipped ~0% year over year to about $2.4 billion (down from $2.400 billion a year ago). Profitability stayed high, with gross margin at roughly 71% and operating margin around 39%, alongside operating income of roughly $937 million on gross profit of about $1.7 billion. Net income fell 18% year over year to about $591 million (down from $721.0 million a year ago). By geography, revenue was concentrated in the United States at roughly $1.2 billion (down ~6% YoY), while China grew near 20% to about $61 million and Japan declined ~24% to roughly $26 million. The quarter generated operating cash flow of about $824 million, and Zoetis returned cash through roughly $500 million of share repurchases and about $219 million in dividends. For the next period, consensus calls for EPS of $1.29 on revenue of $2.234 billion.
About Zoetis Inc.
Zoetis Inc. develops, makes, and sells animal health medicines and related tools, operating in the healthcare sector as a maker of animal therapeutics and diagnostics listed on the NYSE under ZTS. Its business spans veterinary pharmaceuticals, diagnostics, nutrition, and animal health technology, and generated $9.5 billion in FY2025.
Today's Snapshot
ZTS closed 2.1% lower at 79.10, while its sector was flat. Zoetis licensed a new poultry vaccine for use in chickens.
Trading Volume
Above 10d avg 4.5M
5.1M
vs S&P 500 Today
Outperforming Market
+1.40%
Updated: November 20, 2026 at 21:14 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$79.23 - $92.45Sell
- RSI (14)46.23Neutral
- Stochastic %K (14, 3, 3)29.96Neutral
- MACD Level (12, 26)1.25Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.